Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period
References (46)
- et al.
Breakthrough pain: Definition, prevalence and characteristics
Pain
(1990) - et al.
Breakthrough cancer pain: Prevalence and characteristics in patients in Catalonia, Spain
J Pain Symptom Manage
(2002) - et al.
Episodic (breakthrough) pain: Consensus conference of an expert working group of the European Association for Palliative Care
Cancer
(2002) - et al.
A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer
Clin J Pain
(2006) - et al.
Patient-controlled intranasal analgesia: A method for noninvasive postoperative pain management
Anesth Analg.
(1996) - et al.
Intranasal fen-tanyl is an equivalent analgesic to oral morphine in paedi-atric burns patients for dressing changes: A randomised double blind crossover study
Burns.
(2005) An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: A pilot study
J Pain Symptom Manage
(2000)Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain
Palliat Med.
(2000)- et al.
Oral transmu-cosal fentanyl citrate and xerostomia
J Pain Symptom Manage
(2005)
Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study
Clin Ther.
Early pharmacokinetics of nasal fentanyl: Is there a significant arterio-venous difference?
Eur J Clin Pharmacol.
Measurement of pain: Patient preference does not confound pain measurement
Pain
Defining the clinically important difference in pain outcome measures
Pain
Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients
J Natl Cancer Inst.
Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery
Ann Pharmacother
Breakthrough pain in cancer patients: Characteristics, prevalence, and treatment
Oncology (Williston Park)
Breakthrough pain in cancer patients: Characteristics, prevalence, and treatment
Oncology (Williston Park)
Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice [published correction appears in J Pain Symptom Manage. 2001;21:265]
J Pain Symptom Manage
Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network
Palliat Med
Peak plasma concentrations after oral morphine: A systematic review
J Pain Symptom Manage
Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR)
Pain
Nasal administration of opioids for pain management in adults
Acta Anaesthesiol Scand
Cited by (134)
Pediatric emergency department triage-based pain guideline utilizing intranasal fentanyl: Effect of implementation
2018, American Journal of Emergency MedicineThe use of rapid onset fentanyl in children and young people for breakthrough cancer pain
2017, Scandinavian Journal of PainCitation Excerpt :Manufacturer guidance should be followed for other preparations as there is minimal control over the actual dose taken. In opioid tolerant adults with cancer pain intranasal fentanyl has been shown to be effective and generally well tolerated [22]. In paediatrics its use has mainly been confined to emergency medicine where it is administered predominantly to opioid naïve children with acute pain or fractures [6,23,24].
Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial
2016, Journal of Pain and Symptom ManagementCitation Excerpt :It has a bioavailability of 80% and a time to maximal effect (Tmax) of 15–20 minutes, making it a potential appealing option for breathlessness.17,18 FPNS has been found in clinical trials to provide greater and more rapid breakthrough pain relief than placebo19,20 and oral morphine21,22 and was generally well tolerated.23 The efficacy of FPNS has never been examined for dyspnea.